Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by Versant Capital Management Inc

Versant Capital Management Inc grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 1,071.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 164 shares of the medical research company’s stock after acquiring an additional 150 shares during the quarter. Versant Capital Management Inc’s holdings in Charles River Laboratories International were worth $30,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Wolff Wiese Magana LLC purchased a new stake in Charles River Laboratories International during the 3rd quarter worth approximately $32,000. Assetmark Inc. grew its holdings in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Charles River Laboratories International in the 3rd quarter valued at $59,000. Covestor Ltd increased its position in shares of Charles River Laboratories International by 40.9% in the 3rd quarter. Covestor Ltd now owns 327 shares of the medical research company’s stock valued at $65,000 after acquiring an additional 95 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt purchased a new position in Charles River Laboratories International in the 3rd quarter worth $79,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Up 0.1 %

Charles River Laboratories International stock opened at $189.66 on Wednesday. The business has a 50 day simple moving average of $193.01 and a 200-day simple moving average of $199.87. Charles River Laboratories International, Inc. has a 12 month low of $176.48 and a 12 month high of $275.00. The stock has a market capitalization of $9.70 billion, a PE ratio of 23.74, a price-to-earnings-growth ratio of 5.00 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same period last year, the firm posted $2.72 earnings per share. The company’s revenue was down 1.6% compared to the same quarter last year. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on CRL shares. TD Cowen increased their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a report on Monday, November 11th. Evercore ISI increased their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a research note on Monday, October 14th. They set a “sell” rating and a $151.00 price objective for the company. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Finally, Citigroup downgraded shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and decreased their target price for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and a consensus target price of $214.00.

Insider Buying and Selling

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now owns 12,386 shares of the company’s stock, valued at $2,676,862.32. The trade was a 34.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).